(CIDRAP News) – At an Infectious Diseases Society of America (IDSA) symposium in Washington, DC, today on seasonal and pandemic influenza, a group of experts fielded questions from reporters on some of the new trends and emerging issues, including prepandemic strategies for H5N1 avian influenza vaccines, now that some countries are stockpiling them.
(CIDRAP News) – The US Department of Health and Human Services (HHS) has accepted the first batch of H5N1 avian influenza vaccine based on the H5N1 variant known as clade 2.2, which has spread most widely across Asia, Europe, and Africa.
(CIDRAP News) Japan's health ministry today said it was on the verge of approving a plan to administer prepandemic vaccine to healthcare workers, which would make it the world's first country to tap its national stockpile for this purpose.
(CIDRAP News) – China's State Food and Drug Administration (SFDA) yesterday approved the country's first prepandemic H5N1 influenza vaccine, an inactivated whole-virus product made by Sinovac, a Beijing-based biotechnology company.
(CIDRAP News) The United Nations Food and Agriculture Organization (FAO) today warned that H5N1 avian influenza levels in Indonesia's poultry are so high that conditions may be ripe for the type of viral mutation that could spark an influenza pandemic.
(CIDRAP News) Many countries have improved their responses to H5N1 avian influenza outbreaks in poultry in the past year, but the disease remains entrenched in six countries, according to a new report from the United Nations and the World Bank.
(CIDRAP News) A World Health Organization (WHO) working group will meet in Geneva over the next 4 days to try to solve an impasse over how countries share their H5N1 avian influenza virus samples, a disagreement that pits developing countries' demand for affordable vaccines against the global need to monitor virus changes and develop pandemic vaccines.
(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.